Activin A: Complete Research Profile — ACVR1B/ACVR2B Receptor Complex Biology, SMAD2/3 Canonical Signaling, Follistatin Antagonism, Cancer EMT and Cachexia Mechanisms, Reproductive Biology, and Research Applications (2026)

# Activin A: Complete Research Profile — ACVR1B/ACVR2B Receptor Complex Biology, SMAD2/3 Canonical Signaling, Follistatin Antagonism, Cancer EMT and Cachexia Mechanisms, Reproductive Biology, and Research Applications (2026)

Introduction

Activin A is a TGF-β superfamily member formed by the homodimerization of two βA subunits (encoded by INHBA), first isolated from porcine follicular fluid in 1986 by Vale et al. as a factor stimulating follicle-stimulating hormone (FSH) secretion from pituitary gonadotrophs. Despite this reproductive-biology origin, activin A has since been recognized as a pleiotropic cytokine regulating cell fate decisions across virtually every tissue compartment: it governs embryonic germ layer specification, drives inflammatory macrophage activation, induces cancer EMT and metastasis, mediates cancer cachexia, and controls immune cell differentiation including the Th17/Treg balance.

What distinguishes activin A from other TGF-β superfamily members is the precision of its regulatory apparatus. Follistatin (FST) and follistatin-like proteins (FSTL1/3) bind activin A with extraordinary affinity (Kd <1 pM for FST288-activin A) and neutralize it in the extracellular space with exquisite specificity. This tight follistatin-based gating means that small changes in local follistatin:activin A ratios — in the ovary, muscle, bone marrow, or tumor microenvironment — produce large changes in downstream SMAD2/3 activation. Understanding this regulatory circuit is essential for interpreting activin A biology in complex in vitro and in vivo systems.

This profile provides the mechanistic depth required for research investigators designing activin A experiments in reproductive biology, oncology, muscle biology, or immunology settings.

---

Molecular Structure and Biosynthesis

Protein Architecture

Activin A is a disulfide-linked homodimer of two βA subunits (βA/βA). The INHBA gene encodes a 426-amino acid precursor:

• •Signal peptide (aa 1–23)
• •Prodomain (aa 24–309): ~286 aa; non-covalently associated with the mature domain after furin cleavage; modulates secretion efficiency and receptor binding
• •Mature βA domain (aa 310–426): 116 aa; nine conserved cysteines; monomer MW ~13 kDa; dimer ~26 kDa under reducing conditions, ~24 kDa non-reducing
• •Disulfide bond architecture: inter-chain disulfide (C1-C1'' equivalent) plus intra-chain disulfide knot (four cysteines forming the canonical TGF-β cystine knot)

The TGF-β cystine knot fold is shared with all TGF-β superfamily members. The mature activin A dimer is released from the prodomain by furin-family proprotein convertases in the trans-Golgi. Unlike TGF-β1, activin A''s prodomain does not form a latency-associated peptide (LAP)-type complex, so secreted activin A is immediately bioactive and not stored in a latent form.

Activin Isoforms

Multiple activin dimers exist:

Inhibins (α/β heterodimers) are competitive antagonists of activin A at the receptor level: they bind ACVR2A/2B but do not activate type I receptor (ACVR1B) signaling, functioning as dominant-negative decoys.

---

Receptor Complex: ACVR2B and ACVR1B

Signaling Assembly

Activin A signals through a heterotetrameric receptor complex assembled in two steps:

1. Step 1: Activin A binds two type II receptors (ACVR2A or ACVR2B) with high affinity (Kd ~0.1–1 nM). ACVR2B binds activin A with ~10-fold higher affinity than ACVR2A and is the dominant type II receptor for activin A signaling in most tissues.

2. Step 2: The activin A:ACVR2B complex recruits two type I receptors (ACVR1B/ALK4, or ACVR1C/ALK7 in specific contexts). The type II receptor kinase transphosphorylates the type I receptor at the GS domain (Gly-Ser-rich activation loop), allosterically activating type I kinase activity.

3. Step 3: Active ACVR1B phosphorylates R-SMAD proteins (SMAD2 and SMAD3) at their C-terminal SSXS motif (pSer465/467 on SMAD2; pSer423/425 on SMAD3).

Type I Receptor Selectivity: ALK4 vs. ALK7

• •ALK4 (ACVR1B): primary activin A type I receptor; ubiquitously expressed; drives canonical SMAD2/3 signaling
• •ALK7 (ACVR1C): expressed in pancreas, brain, adipose; preferentially activated by activin B and activin AB; role in pancreatic beta-cell apoptosis and fat cell differentiation
• •ALK5 (TGFBR1): the type I receptor for TGF-β1; can heterodimerize with ACVR2B in some contexts — responsible for TGF-β/activin crosstalk; SB431542 (ALK4/5/7 inhibitor) blocks both activin and TGF-β signaling

SMAD2 vs. SMAD3 Differential Signaling

Despite being phosphorylated by the same kinase, SMAD2 and SMAD3 have distinct functional profiles:

For activin A specifically:

• •SMAD2: drives Nodal co-receptor Cripto-dependent signaling; primary in early embryogenesis and stem cell differentiation
• •SMAD3: drives most adult activin A transcriptional responses including FSH regulation, EMT, immune suppression, and inflammatory gene programs

Investigators should use phospho-specific antibodies for pSMAD2 (S465/467, CST #3108) and pSMAD3 (S423/425, CST #9520) separately rather than pan-pSMAD2/3 blots to resolve pathway-specific effects.

---

Follistatin Antagonism: The Master Regulator

Follistatin Isoforms

Follistatin (FST) is encoded by a single gene generating multiple isoforms through alternative splicing and proteolytic cleavage:

• •FST288: 288 aa; high-affinity activin A binding (Kd ~1–5 pM); predominantly cell-surface-associated (HSPG-tethered via the C-terminal tail)
• •FST315: 315 aa; slightly lower affinity; circulates freely in serum
• •FST303: proteolytic product; intermediate properties

FST288 cell-surface association means it creates a local "clearance zone" around activin A-producing cells — capturing secreted activin A immediately and preventing paracrine diffusion. This geometry is critical for understanding why measuring secreted activin A in conditioned medium underestimates total activin A production in FST-expressing systems.

Binding Mechanism

FST wraps around the activin A dimer, contacting both βA subunits and sterically blocking the type II receptor binding sites. The 1:1 FST:activin A complex (actually 2 FST molecules per activin A homodimer) has KD ~1 pM — one of the tightest non-covalent cytokine:antagonist interactions known in biology. Key implications for research:

1. Follistatin neutralizes activin A non-reversibly on the experimental timescale — FST:activin A complexes are kinetically stable; a 30-min pre-incubation of activin A with FST at 1:1 molar ratio effectively eliminates receptor-accessible ligand for hours

2. Serum contains FST (~2–3 nM total) — standard 10% FBS culture medium carries ~0.2–0.3 nM FST, potentially masking activin A activity at concentrations below ~0.5 nM; use serum-free or defined medium for precise dose-response assays

3. Measuring bioactive activin A vs. total activin A: standard ELISAs detect total activin A regardless of FST binding; bioactive fraction requires a cell-based reporter assay (SMAD-luciferase) or FST depletion before measurement

---

Canonical SMAD2/3 Signaling and Transcriptional Outputs

SMAD Complex Assembly and Nuclear Import

Phospho-SMAD2/3 (pSMAD2/3) forms heterotrimers with SMAD4 (common mediator SMAD):

• •2 pR-SMAD + 1 SMAD4 per complex
• •Nuclear import via importin-β
• •Co-activator recruitment: p300/CBP, FOXH1, FAST1/2 (Forkhead box H1)
• •Co-repressor contexts: SKI, SKIL (SNO), c-SKI — oncoproteins that bind SMAD3:SMAD4 and recruit HDAC complexes to repress activin target genes

Key Target Genes

Activin A/SMAD2/3 transcriptional targets include:

The FST gene is a direct SMAD3 target, creating an integral negative feedback: activin A → SMAD3 → FST → extracellular activin A neutralization → reduced SMAD3 activation. This feedback controls the amplitude and duration of activin A signaling pulses.

---

Reproductive Biology

FSH Regulation

In the pituitary, activin A from gonadotroph paracrine signaling (and from activin-producing follicles at the systemic level) stimulates:

• •FSH-β subunit (FSHB) transcription via SMAD3 + FOXL2 co-binding at the FSHB promoter
• •Upregulation of activin type II receptors on gonadotrophs
• •Synergy with GnRH to amplify FSH burst at mid-cycle

Inhibin A (α/βA) competes with activin A at ACVR2A/B on gonadotrophs without signaling, suppressing FSH. The inhibin:activin ratio in follicular fluid shifts dramatically across the menstrual cycle, governing FSH dynamics. For in vitro pituitary research, αT3-1 or LβT2 gonadotroph cell lines treated with activin A (1–10 ng/mL) + follistatin controls are the standard model system.

Ovarian Folliculogenesis

In granulosa cells:

• •Activin A (intra-follicular, autocrine) stimulates FSH receptor (FSHR) upregulation
• •Activin A + FSH synergistically drive aromatase (CYP19A1) expression → estradiol synthesis
• •Activin A suppresses androgen production by theca cells (paracrine anti-androgen effect)
• •Shift from activin to inhibin dominance in the pre-ovulatory follicle marks selection and maturation

Decidualization and Implantation

Activin A is produced by decidualizing stromal cells and modulates uterine NK cell function and trophoblast invasion depth. FST-activin A balance in the decidua regulates implantation window biology and is an active research area in early pregnancy biology.

---

Cancer Biology: EMT, Invasion, and Cachexia

Activin A in EMT

In epithelial cancers, activin A drives EMT through SMAD3-dependent transcription:

• •Snail/Slug upregulation → E-cadherin repression → epithelial junction dissolution
• •ZEB1/ZEB2 induction → E-cadherin, miR-200 family suppression
• •Vimentin, N-cadherin, fibronectin upregulation → mesenchymal phenotype

In pancreatic ductal adenocarcinoma (PDAC), activin A is co-opted from its normal role in pancreatic ductal cell differentiation into a driver of SMAD4-wild-type tumor cell invasion. PDAC patients with high serum activin A have significantly worse prognosis. Notably, SMAD4 loss (occurring in ~50% of PDAC) uncouples activin signaling from canonical tumor suppression while sparing non-canonical activin A effects (p38/JNK, PI3K).

Non-SMAD Activin A Signaling in Cancer

In SMAD4-mutant or SMAD4-silenced cancer cells, activin A activates non-canonical pathways:

• •PI3K-AKT: ACVR2B → TRAF6 → PI3K; promotes survival
• •p38 MAPK: TAK1-dependent; drives inflammatory gene expression
• •ERK1/2: in some cancer cell lines via ACVR1B → Src → Ras crosstalk
• •mTORC1: via AKT; drives protein synthesis

These SMAD4-independent pathways explain why many cancers with SMAD4 loss do not simply silence activin A signaling — instead, they redirect it toward survival and invasion outputs.

Cancer Cachexia

Activin A is a primary driver of cancer cachexia — the muscle wasting syndrome affecting ~50% of cancer patients. Mechanistically:

• •Tumor-derived activin A binds ACVR2B on skeletal muscle
• •ACVR2B → ALK4/7 → pSMAD2/3 in myocytes
• •pSMAD3 → FOXO3a → MuRF1/MAFBx (atrogene) expression → ubiquitin-proteasome degradation of sarcomere proteins
• •Simultaneously suppresses mTORC1/AKT-driven protein synthesis → net negative protein balance

The ACVR2B decoy receptor (ActRIIB-Fc) blocks activin A/B, myostatin, and GDF-11 simultaneously and has been studied as a muscle wasting research tool.

For muscle wasting research assays:

• •C2C12 myotube atrophy model: activin A (50–200 ng/mL) × 48–72h → reduced myotube diameter, atrogene upregulation, decreased MyHC expression
• •Myostatin (GDF-8) at 100–500 ng/mL serves as the positive atrophy control
• •ACVR2B-Fc (1–10 µg/mL) as rescue control

---

Immune Biology

Macrophage Activation

Activin A is rapidly produced by macrophages and dendritic cells following TLR activation (LPS, poly I:C). Macrophage-derived activin A:

• •Acts in autocrine/paracrine manner to amplify IL-6, TNF-α production via NF-κB
• •Drives M1-like inflammatory polarization; suppresses IL-10 production
• •Promotes DC maturation (upregulates MHC II, CD80/86)

Th17/Treg Balance

Activin A promotes Th17 differentiation and suppresses Treg:

• •SMAD3 cooperates with RORγt to drive IL17A and RORC transcription
• •Activin A inhibits Foxp3 expression and Treg function in inflammatory contexts
• •This Th17-promoting effect of activin A is opposed by follistatin-mediated inhibition

---

Pathway Inhibition Research Tools

Small Molecule ACVR1B/ALK4/5/7 Inhibitors

Critical design consideration: SB431542/A 83-01 at standard research concentrations (1–10 µM) block both activin A (ALK4) and TGF-β (ALK5) signaling simultaneously. To isolate activin A-specific effects, use follistatin (FST315, 500 ng/mL–1 µg/mL) as the activin A-selective antagonist — FST does not neutralize TGF-β.

Biologics

• •Follistatin 288 and 315 (R&D Systems; Cat# 669-FO and 1288-FO): activin A-selective antagonists; FST288 at 200–500 ng/mL neutralizes 10–100 ng/mL activin A
• •Anti-activin A antibody (R&D Systems Cat# MAB3381): neutralizing mAb; use at 5–10 µg/mL to neutralize 10 ng/mL activin A
• •ACVR2B-Fc decoy (ActRIIB-Fc): neutralizes activin A, activin B, myostatin, GDF-11; less selective but useful for pan-ACVR2B ligand blockade

---

Experimental Protocols

SMAD2/3 Phosphorylation Assay

1. Starve cells in serum-free medium for 4h (serum contains FST that partially masks activin A)

2. Stimulate with rhActivin A (R&D Systems Cat# 338-AC; 1–100 ng/mL) for 30–60 min

3. Lyse in RIPA + PhosSTOP

4. Western: pSMAD2 (S465/467, CST #3108, 1:1000); pSMAD3 (S423/425, CST #9520, 1:1000); total SMAD2/3 (CST #8685)

5. Controls: SB431542 (10 µM, 30 min pre-treatment) → complete pSMAD2/3 block; TGF-β1 (10 ng/mL) → pSMAD2/3 via ALK5 (positive control)

6. To confirm activin A specificity: add FST315 (500 ng/mL) co-incubated with activin A → >90% pSMAD2/3 reduction

SMAD Luciferase Reporter Assay

The (CAGA)₁₂-luciferase reporter contains 12 SMAD-binding elements (CAGA boxes) driving firefly luciferase:

1. Transfect cells with (CAGA)₁₂-luc + Renilla-CMV (normalization) at 10:1 ratio

2. Allow 24h expression recovery

3. Stimulate with activin A (1–100 ng/mL) ± FST (0.1–1 µg/mL) ± SB431542 (10 µM) × 16–24h

4. Dual-luciferase readout; normalize firefly/Renilla

5. Activin A EC₅₀ in this assay: typically 1–10 ng/mL in most epithelial lines

Note: (CAGA)₁₂ responds to both activin A (ALK4/SMAD3) and TGF-β (ALK5/SMAD3). Use FST to isolate activin A contribution.

C2C12 Myotube Atrophy Model

1. Differentiate C2C12 myoblasts for 5–7 days in DMEM + 2% horse serum until multinucleated myotubes form

2. Treat myotubes with activin A (50–200 ng/mL) in differentiation medium × 48–72h

3. Quantify: myotube diameter by brightfield imaging (ImageJ; measure 30 myotubes/condition); MuRF1 and MAFBx mRNA by RT-qPCR; MyHC protein by western

4. Expected: activin A at 100 ng/mL → ~30–40% reduction in myotube diameter; MuRF1/MAFBx upregulation 3–5-fold

5. Rescue control: ACVR2B-Fc (2 µg/mL) co-treatment → prevents atrophy

---

PubMed-Cited References

1. Vale W, Rivier J, Vaughan J, et al. Purification and characterization of an FSH releasing protein from porcine ovarian follicular fluid. Nature. 1986;321(6072):776-779. PMID: 3012369

2. Tsuchida K, Nakatani M, Uezumi A, Murakami T, Cui X. Signal transduction pathway through activin receptors as a therapeutic target of musculoskeletal diseases and cancer. Endocr J. 2008;55(1):11-21.

3. Patel MS, Lee J, Wells C, et al. Gene expression profiling of cachexia-associated adipose tissue links cancer and adipose tissue alterations. J Cachexia Sarcopenia Muscle. 2019;10(4):774-789.

4. Ogino H, Yano S, Kakiuchi S, et al. Follistatin suppresses the production of experimental multiple-organ metastasis by small cell lung cancer cells in natural killer cell-depleted SCID mice. Clin Cancer Res. 2008;14(3):660-667.

5. Bloise E, Ciarmela P, Dela Cruz C, Luisi S, Petraglia F, Reis FM. Activin A in mammalian physiology. Physiol Rev. 2019;99(1):739-780.

6. Zhou X, Wang JL, Lu J, et al. Reversal of cancer cachexia and muscle wasting by ActRIIB antagonism leads to prolonged survival. Cell. 2010;142(4):531-543. PMID: 20723755

---

Summary for Research Investigators

Activin A is a TGF-β superfamily homodimer (βA/βA) that signals through ACVR2B → ACVR1B (ALK4) → pSMAD2/3 with tight regulation by follistatin''s picomolar-affinity neutralization. Its biology spans FSH/reproductive axis control, cancer EMT via SMAD3/Snail, muscle cachexia via ACVR2B/atrogene induction, and inflammatory macrophage/Th17 amplification.

For experimental design: (1) use serum-free conditions for activin A dose-response assays to avoid FST masking; (2) distinguish activin A (FST-sensitive) from TGF-β (FST-insensitive) contributions using FST315 as the selective activin A antagonist; (3) use separate pSMAD2 and pSMAD3 antibodies to resolve SMAD-specific programs; (4) in SMAD4-null cancer lines, expect redirected signaling to PI3K/p38/ERK rather than canonical SMAD nuclear output; (5) in myotube atrophy assays, include myostatin positive control and ACVR2B-Fc rescue to confirm receptor specificity.

References

• •PMID: 42692621
• •PMID: 42722136
• •PMID: 42692621

All materials described in this profile are for Research Use Only (RUO). Not for diagnostic, therapeutic, or human/animal administration purposes.